A Phase 2a Study of PPI-668 in Combination With BI 207127 and Faldaprevir, With and Without Ribavirin, in Treatment-Naive Patients With Chronic Hepatitis C (HCV Genotype 1a).
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2015
At a glance
- Drugs Deleobuvir (Primary) ; Faldaprevir (Primary) ; Ravidasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Presidio Pharmaceuticals
- 21 Jan 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 09 Oct 2014 According to the ClinicalTrials.gov reocrd, planned end date changed 1 Sep 2014 to 1 Oct 2014.
- 29 Aug 2014 According to the ClinicalTrials.gov reocrd, planned end date changed from 1 Aug 2014 to 1 Sep 2014.